Individualized predictive signatures for 5‐fluorouracil‐based chemotherapy in right‐ and left‐sided colon cancer

5‐Fluorouracil (5‐FU)‐based adjuvant chemotherapy (ACT) is widely used for the treatment of colon cancer. Colon cancers with different primary tumor locations are clinically and molecularly distinct, implied through their response to 5‐FU‐based ACT. In this work, using 69 and 133 samples of patients with stage II‐III right‐sided and left‐sided colon cancer (RCC and LCC) treated with post‐surgery 5‐FU‐based ACT, we preselected gene pairs whose relative expression orderings were significantly correlated with the disease‐free survival of patients by univariate Cox proportional hazards model. Then, from the identified prognostic‐related gene pairs, a forward‐stepwise selection algorithm was formulated to search for an optimal subset of gene pairs that resulted in the highest concordance index, referred to as the gene pair signature (GPS). We identified prognostic signatures, 3‐GPS and 5‐GPS, for predicting response to 5‐FU‐based ACT of patients with RCC and LCC, respectively, which were validated in independent datasets of GSE14333 and GSE72970. With the aid of the signatures, the transcriptional and genomic characteristics between the predicted responders and non‐responders were explored. Notably, both in RCC and LCC, the predicted responders to 5‐FU‐based ACT were characterized by hypermutation, whereas the predicted non‐responders were characterized by frequent copy number alternations. Finally, in comparison with the established relative expression ordering‐based signature, which was developed without considering the differences between RCC and LCC, the newly proposed signatures had a better predictive performance. In conclusion, 3‐GPS or 5‐GPS can robustly predict response to 5‐FU‐based ACT for patients with RCC or LCC, respectively, in an individual level.

[1]  M. Sehested,et al.  Single agent‐ and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells , 2012, The journal of gene medicine.

[2]  A. Nicholson,et al.  Impact of collection and storage of lung tumor tissue on whole genome expression profiling. , 2012, The Journal of molecular diagnostics : JMD.

[3]  X. Fang,et al.  Different treatment strategies and molecular features between right-sided and left-sided colon cancers. , 2015, World journal of gastroenterology.

[4]  M. Nitti,et al.  Role of Glutathione in Cancer Progression and Chemoresistance , 2013, Oxidative medicine and cellular longevity.

[5]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[6]  Lorena Rossi,et al.  Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. , 2007, Pharmacological research.

[7]  R. Seetharam,et al.  Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance , 2009, Ecancermedicalscience.

[8]  B. Henderson,et al.  Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy , 2014, Oncotarget.

[9]  E. Van Cutsem,et al.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials , 2017, JAMA oncology.

[10]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[11]  M. Washington,et al.  Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway , 2014, British Journal of Cancer.

[12]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[13]  F. Gu,et al.  High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer , 2015, Journal of Cancer.

[14]  T. Ørntoft,et al.  Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer , 2009, Clinical Cancer Research.

[15]  Shuji Ogino,et al.  Colorectal cancer: a tale of two sides or a continuum? , 2012, Gut.

[16]  Xiaolong Yang,et al.  The Hippo pathway in chemotherapeutic drug resistance , 2015, International journal of cancer.

[17]  Zheng Guo,et al.  Differential expression analysis for individual cancer samples based on robust within-sample relative gene expression orderings across multiple profiling platforms , 2016, Oncotarget.

[18]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[19]  Yunyan Gu,et al.  An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy , 2016, British Journal of Cancer.

[20]  G. Hong,et al.  Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy , 2016, Oncogenesis.

[21]  Y. Zha,et al.  Downregulation of Rap1 promotes 5-fluorouracil-induced apoptosis in hepatocellular carcinoma cell line HepG2. , 2014, Oncology reports.

[22]  A. Oshima,et al.  A Gene Expression Signature of Acquired Chemoresistance to Cisplatin and Fluorouracil Combination Chemotherapy in Gastric Cancer Patients , 2011, PloS one.

[23]  Mira Ayadi,et al.  Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.

[24]  A. Jemal,et al.  Colorectal cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[25]  Xinbing Sui,et al.  JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy , 2014, Scientific Reports.

[26]  Douglas G Altman,et al.  The logrank test , 2004, BMJ : British Medical Journal.

[27]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[28]  M. Shakibaei,et al.  Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. , 2015, Biochemical pharmacology.

[29]  R. Labianca,et al.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  T. Jin,et al.  MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression , 2014, Oncotarget.

[31]  C. Ulrich,et al.  Polymorphisms in folate‐metabolizing enzymes and response to 5‐fluorouracil among patients with stage II or III rectal cancer (INT‐0144; SWOG 9304) , 2014, Cancer.

[32]  Jeffrey J Meyer,et al.  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .

[33]  H. Lehrach,et al.  5-Fluorouracil affects assembly of stress granules based on RNA incorporation , 2014, Nucleic acids research.

[34]  Murim Choi,et al.  Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism , 2015, eLife.

[35]  Yan Liu,et al.  Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[36]  Yan Wu,et al.  AMPK activator AICAR promotes 5-FU-induced apoptosis in gastric cancer cells , 2015, Molecular and Cellular Biochemistry.

[37]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[38]  Libin Chen,et al.  Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer , 2016, Briefings Bioinform..

[39]  Ahmed Kamel,et al.  Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[40]  Na Li,et al.  Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples , 2016, Oncotarget.

[41]  H. Lenz,et al.  Primary tumor location as a prognostic factor in metastatic colorectal cancer. , 2015, Journal of the National Cancer Institute.

[42]  M. Henry,et al.  Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles , 2017, Scientific Reports.

[43]  Purusottam Mohapatra,et al.  5-fluorouracil increases the chemopreventive potentials of resveratrol through DNA damage and MAPK signaling pathway in human colorectal cancer cells. , 2011, Oncology research.

[44]  Susumu Goto,et al.  KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..

[45]  Y. Kitagawa,et al.  Evaluation of 5-Fluorouracil Metabolic Enzymes as Predictors of Response to Adjuvant Chemotherapy Outcomes in Patients with Stage II/III Colorectal Cancer: A Decision-Curve Analysis , 2014, World Journal of Surgery.

[46]  M. Ychou,et al.  Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. , 2017, European journal of cancer.

[47]  Zhe-Sheng Chen,et al.  Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases , 2011, The FEBS journal.

[48]  Qiang Sun,et al.  The influence of cancer tissue sampling on the identification of cancer characteristics , 2015, Scientific Reports.

[49]  E. Gottlieb,et al.  Targeting metabolic transformation for cancer therapy , 2010, Nature Reviews Cancer.

[50]  S. Carr,et al.  Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver , 2014, BMC Cancer.

[51]  V. Golubovskaya,et al.  Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy , 2013, Cancer biology & therapy.

[52]  J. Downward Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[53]  Jinfeng Zou,et al.  Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer. , 2016, JAMA oncology.